Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The registered capital of the newly founded company is € 50 million
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The new campus has been designed as an employee-centred experience and ecosystem zone
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Subscribe To Our Newsletter & Stay Updated
